Literature DB >> 10569748

Validation and characterization of a human volunteer challenge model for cholera by using frozen bacteria of the new Vibrio cholerae epidemic serotype, O139.

M B Cohen1, R A Giannella, G A Losonsky, D R Lang, S Parker, J A Hawkins, C Gunther, G A Schiff.   

Abstract

Until recently, all epidemic strains of Vibrio cholerae were of the O1 serotype. Current epidemics have also been caused by a new serotype, Vibrio cholerae O139. Although the pathogenesis and clinical features of O139 cholera are similar to those of O1 cholera, immunity to serotype O1 does not confer immunity to serotype O139. Therefore, prior to beginning vaccine efficacy studies, we sought to validate the use of a large standardized frozen inoculum of virulent V. cholerae O139 4260B for use in a human volunteer challenge model. Healthy volunteers (n = 25) were recruited for an Internal Review Board-approved inpatient dose-escalation challenge. Our goal was to identify a dose at which the cholera attack rate and the geometric mean purge were sufficient for determining vaccine efficacy against moderate and severe disease. At a dose of 10(5) CFU, 8 of 10 volunteers experienced purging and had a positive stool culture for V. cholerae. However, at this dose, the geometric mean stool volume of 2,175 g was insufficient by study criteria. At a dose of 10(6) CFU, 14 of 15 volunteers experienced purging, with a geometric mean stool volume of 5,621 g. Disease severity was significantly greater in volunteers with blood group O than those with non-O blood types (10,353 g versus 3,555 g, P < 0.001). Following challenge, all volunteers demonstrated a significant rise in antitoxin antibodies but the serum vibriocidal titer was attenuated compared to that seen after challenge with an O1 strain. This model provides a reproducible illness of sufficient severity for testing the efficacies of new O139 or combined O1-O139 vaccines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10569748      PMCID: PMC97040          DOI: 10.1128/IAI.67.12.6346-6349.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy.

Authors:  J D Clemens; D A Sack; J R Harris; J Chakraborty; M R Khan; S Huda; F Ahmed; J Gomes; M R Rao; A M Svennerholm
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

2.  Validation of a volunteer model of cholera with frozen bacteria as the challenge.

Authors:  D A Sack; C O Tacket; M B Cohen; R B Sack; G A Losonsky; J Shimko; J P Nataro; R Edelman; M M Levine; R A Giannella; G Schiff; D Lang
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

Review 3.  Cholera.

Authors:  J B Kaper; J G Morris; M M Levine
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

4.  Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Cholera Working Group, International Centre for Diarrhoeal Diseases Research, Bangladesh.

Authors: 
Journal:  Lancet       Date:  1993-08-14       Impact factor: 79.321

5.  Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.

Authors:  C O Tacket; M B Cohen; S S Wasserman; G Losonsky; S Livio; K Kotloff; R Edelman; J B Kaper; S J Cryz; R A Giannella; G Schiff; M M Levine
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

6.  Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers.

Authors:  J G Morris; G E Losonsky; J A Johnson; C O Tacket; J P Nataro; P Panigrahi; M M Levin
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

7.  Predisposition for cholera of individuals with O blood group. Possible evolutionary significance.

Authors:  R I Glass; J Holmgren; C E Haley; M R Khan; A M Svennerholm; B J Stoll; K M Belayet Hossain; R E Black; M Yunus; D Barua
Journal:  Am J Epidemiol       Date:  1985-06       Impact factor: 4.897

Review 8.  Epidemiology of cholera in the Americas.

Authors:  P A Blake
Journal:  Gastroenterol Clin North Am       Date:  1993-09       Impact factor: 3.806

9.  Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O.

Authors:  R Lagos; A Avendaño; V Prado; I Horwitz; S Wasserman; G Losonsky; S Cryz; J B Kaper; M M Levine
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

10.  Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge.

Authors:  C O Tacket; G Losonsky; J P Nataro; L Comstock; J Michalski; R Edelman; J B Kaper; M M Levine
Journal:  J Infect Dis       Date:  1995-09       Impact factor: 5.226

View more
  8 in total

1.  Ethical Criteria for Human Challenge Studies in Infectious Diseases.

Authors:  Ben Bambery; Michael Selgelid; Charles Weijer; Julian Savulescu; Andrew J Pollard
Journal:  Public Health Ethics       Date:  2015-09-27       Impact factor: 1.940

2.  The utility of human challenge studies in vaccine development: lessons learned from cholera.

Authors:  Debbie-Ann T Shirley; Monica A McArthur
Journal:  Vaccine (Auckl)       Date:  2011-10

Review 3.  The incubation period of cholera: a systematic review.

Authors:  Andrew S Azman; Kara E Rudolph; Derek A T Cummings; Justin Lessler
Journal:  J Infect       Date:  2012-11-29       Impact factor: 6.072

4.  Field evaluation of a rapid immunochromatographic dipstick test for the diagnosis of cholera in a high-risk population.

Authors:  Xuan-Yi Wang; M Ansaruzzaman; Raul Vaz; Catarina Mondlane; Marcelino E S Lucas; Lorenz von Seidlein; Jacqueline L Deen; Sonia Ampuero; Mahesh Puri; Taesung Park; G B Nair; John D Clemens; Claire-Lise Chaignat; Minoarisoa Rajerison; Farida Nato; Jean-Michel Fournier
Journal:  BMC Infect Dis       Date:  2006-02-01       Impact factor: 3.090

5.  Dynamics of Vibrio cholerae abundance in Austrian saline lakes, assessed with quantitative solid-phase cytometry.

Authors:  Sonja Schauer; Stefan Jakwerth; Rupert Bliem; Julia Baudart; Philippe Lebaron; Steliana Huhulescu; Michael Kundi; Alois Herzig; Andreas H Farnleitner; Regina Sommer; Alexander Kirschner
Journal:  Environ Microbiol       Date:  2015-05-18       Impact factor: 5.491

6.  Application of three different methods to determine the prevalence, the abundance and the environmental drivers of culturable Vibrio cholerae in fresh and brackish bathing waters.

Authors:  A K T Kirschner; S Pleininger; S Jakwerth; S Rehak; A H Farnleitner; S Huhulescu; A Indra
Journal:  J Appl Microbiol       Date:  2018-08-13       Impact factor: 3.772

7.  Fucose-Galactose Polymers Inhibit Cholera Toxin Binding to Fucosylated Structures and Galactose-Dependent Intoxication of Human Enteroids.

Authors:  Jakob Cervin; Andrew Boucher; Gyusaang Youn; Per Björklund; Ville Wallenius; Lynda Mottram; Nicole S Sampson; Ulf Yrlid
Journal:  ACS Infect Dis       Date:  2020-03-19       Impact factor: 5.084

Review 8.  Experimental human hookworm infection: a narrative historical review.

Authors:  Paul R Chapman; Paul Giacomin; Alex Loukas; James S McCarthy
Journal:  PLoS Negl Trop Dis       Date:  2021-12-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.